A phase I study of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel, doxorubicin, and cyclophosphamide (NAC) in patients with stages II-III HER2-negative breast cancer

被引：2
|
作者：
Khong, H. T.
Dyess, D. L.
Butler, T. W.
Dumlao, T. L.
机构：
[1] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA
[2] Univ S Alabama, Dept Surg, Mobile, AL 36688 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11519
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer
    Yang, Miaomiao
    Qu, Huajun
    Liu, Aina
    Liu, Jiannan
    Sun, Ping
    Li, Hua
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (07) : 1561 - 1566
  • [2] Evaluation of neoadjuvant weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer
    Nagayama, A.
    Matsui, A.
    Tachibana, A.
    Suzuki, N.
    Hirata, M.
    Oishi, Y.
    Hamaguchi, Y.
    Murata, Y.
    Okamoto, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety
    Shimada, Hiroko
    Ueda, Shigeto
    Saeki, Toshiaki
    Shigekawa, Takashi
    Takeuchi, Hideki
    Hirokawa, Eiko
    Sugitani, Ikuko
    Sugiyama, Michiko
    Takahashi, Takao
    Matsuura, Kazuo
    Yamane, Tomohiko
    Kuji, Ichiei
    Hasebe, Takahiro
    Osaki, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 642 - 649
  • [4] Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients
    Fabi, Alessandra
    Ferretti, Gianluigi
    Malaguti, Paola
    Gasparro, Simona
    Nistico, Cecilia
    Arpino, Grazia
    Papaldo, Paola
    Russillo, Michelangelo
    Catania, Giovanna
    Schettini, Francesco
    Giannarelli, Diana
    Cognetti, Francesco
    FUTURE ONCOLOGY, 2020, 16 (22) : 1629 - 1637
  • [5] Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study
    Sinclair, N.
    Abu-Khalaf, M. M.
    Sakr, B. J.
    Rizack, T.
    Lannin, D. R.
    Gass, J. S.
    Strenger, R.
    Bossuyt, V.
    Fenton, M. A.
    Harris, L.
    Sikov, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
    Lv, Zhi-Dong
    Song, Hong-Ming
    Niu, Zhao-He
    Nie, Gang
    Zheng, Shuai
    Xu, Ying-Ying
    Gong, Wei
    Wang, Hai-Bo
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [7] Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer
    Mrozek, Ewa
    Layman, Rachel
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam
    Vecchione, Andrea
    Knopp, Michael V.
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2014, 14 (04) : 228 - 234
  • [8] Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m2) Followed by Fluorouracil, Epirubicin, and Cyclophosphamide Therapy as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
    Kojima, Yasuyuki
    Kawamoto, Hisanori
    Nishikawa, Toru
    Hayami, Ryosuke
    Shimo, Arata
    Haku, Ei
    Akiyama, Kyoko
    Tsugawa, Koichiro
    CLINICAL BREAST CANCER, 2018, 18 (05) : 374 - 379
  • [9] Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer
    Matsui, Akira
    Tatibana, Akihiko
    Suzuki, Noriyuki
    Hirata, Masaru
    Oishi, Yoko
    Hamaguchi, Youhei
    Murata, Yuya
    Nagayama, Aiko
    Iwata, Yuko
    Okamoto, Yasushi
    ANTICANCER RESEARCH, 2017, 37 (11) : 6481 - 6488
  • [10] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
12345